Home / Content / B2B Connect / Pharma / Zydus Cadila receives US FDA nod for antifungal drug nystatin

Zydus Cadila receives US FDA nod for antifungal drug nystatin

The product, nystatin topical powder, will be manufactured at US facility of Zydus' arm Nesher

Premium

Last Updated : Jun 12 2017 | 4:18 PM IST

Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has recevied final approval from the US Food & Drug Administration (FDA) to market nystatin topical powder (100,000 units per gram). The drug will be produced at the Nesher Pharmaceuticals' manufacturing facility located at St. Louis, Missouri (USA). Nystatin topical powder is an antifungal antibiotic used to treat skin infections caused by yeast.

The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in